Duleep began his career in social security, working first for the Benefits Agency before moving into welfare rights advice. He managed the welfare rights service at Action for Blind People before joining the policy team at the Royal National Institute for Deaf People (RNDI) where he led on social security and employment policy.
Duleep joined Macmillan in 2004 and has played a leading role in the charity’s campaigns including hospital parking, prescription charges, employment and welfare reform. He led a workstream of the National Cancer Survivorship Initiative (NCSI) which developed and tested tools and services to improve benefit advice and return to work support for cancer patients.
Miles joined the Department of Health in 2002 from the Benefits Agency and has been responsible for significant healthcare reform programmes, including the introduction of legislation on care trusts, delivery of Commissioning a Patient-led NHS, and Local Delivery Planning.
He has also led programmes to reduce burdens and bureaucracy on the front line, introduced new planning regimes for the NHS, and led the NHS wide restructuring of Strategic Health Authorities and Primary Care Trusts.
He is the Departmental lead for a range of areas including long term conditions, innovation, including Regional Innovation Funds, and NHS Global.
Dr Junaid Bajwa
Dr Junaid Bajwa is a GP principal in Greenwich, London. He was on NHS Greenwich’s professional executive committee (PEC), which enabled him to assist in the commissioning and pathway redesign of a number of services (diabetes, ENT, cardiology, Referral Management Service). Through PEC, he had been seconded to the local practice-based commissioning to further assist in the development of their local cluster-specific commissioning projects.
He is currently an RCGP Clinical Commissioning Champion, Vice Chair of the local LMC, and is working towards completing his Masters in Healthcare Commissioning at the University of Birmingham
Nicki Bromwich BSc, RGN
Nicki Bromwich (BSc, RGN) is a senior manager with experience, in quality, commissioning and service redesign, at a national and local level. Her previous roles include, National Audit Manager at NICE, and Head of Quality Improvement at Chiltern & South Bucks PCT. In 2008 Nicki was appointed Assistant Director Urgent Care at NHS Buckinghamshire with responsibility for unscheduled acute and community care commissioning, service redesign and long term condition management. Nicki has commissioned three new and integrated respiratory services for 2012/13: Home Oxygen –Assessment and Review; Pulmonary Rehabilitation; and a community respiratory service focused on management of exacerbation and admission avoidance.
Columnist, The Times and Chair of Trustees, Demos
Philip Collins is a columnist on The Times and the chair of the think tank Demos. He also runs a speech writing company. Until he joined The Times he was the Chief Speech Writer to the Prime Minister, Tony Blair. Before that he had been the Director of the think tank the Social Market Foundation, a top-ranked Equity Strategist in investment banking and a research assistant in both politics and television.
Sir Andrew Dillon
Chief Executive, NICE
Andrew Dillon joined the NHS in1975 and held a number of senior management positions, including General Manager of the Royal Free Hospital and Chief Executive of St George’s Healthcare NHS Trust, before joining the National Institute for Health and Clinical Excellence as its founding Chief Executive in 1999.
Prof. Michael Drummond BSc, MCom, DPhil
Professor of Health Economics, University of York
Michael Drummond, is Professor of Health Economics and former Director of the Centre for health Economics at the University of York. His particular field of interest is in the economic evaluation of health care treatments and programmes. He has undertaken evaluations in a wide range of medical fields including care of the elderly, neonatal intensive care, immunization programmes, services for people with AIDS, eye health care and pharmaceuticals.
He is the author of two major textbooks and more than 600 scientific papers, and has acted as a consultant to the World Health Organization and the European Union. He has been President of the International Society of Technology Assessment in Health Care, and the International Society for Pharmacoeconomics and Outcomes Research. In October 2010 he was made a member of the Institute of Medicine in the USA and is currently a Principal Consultant for OptumInsight.
Chief Executive, Beating Bowel Cancer
Mark joined Beating Bowel Cancer in July 2009. Immediately prior to that he was Director of Policy and Communications at the Royal College of General Practitioners. Mark has a background in a number of high profile organisations including the Royal College of Nursing, Diabetes UK, the BBC and the homelessness charity, Crisis.
Mark started his career working for Action on Smoking and Health, lobbying for a ban on tobacco advertising and a ban on smoking in public places. Mark Flannagan has also been a Trustee of Groundwork, the sustainability and regeneration charity. He sits on the Department of Health’s Bowel Cancer Screening Advisory Group and also the Public Health Engagement Group. He has a degree in Medieval History which included Medicine in the Middle Ages as a special subject.
Dr. Susan Galbraith
Head of Oncology, Innovative Medicines Research Unit, AstraZeneca
Susan Galbraith trained as a Clinical Oncologist in the United Kingdom. She studied Medicine at Manchester and Cambridge Universities, completing internal medicine training in hospitals in Cambridge and East Anglia. She was admitted to Membership of the Royal College of Physicians in 1992, and then trained in Clinical Oncology in London. She gained Fellowship of the Royal College of Radiologists in 1997. She then completed a PhD at the University of London involving translational work on a vascular-targeting agent.
Susan joined the Clinical Discovery Oncology group at Bristol-Myers Squibb in 2001. She led the brivanib Early Development Team and fostered the integration of pharmcogenomics and imaging biomarkers into many Phase I and II trials. Susan was closely involved in the in-licensing of ipilimumab from Medarex, elotuzumab from PDL, the acquisitions of Adnexus and Medarex and research collaborations with Exelixis. She held increasing levels of responsibility becoming VP for Oncology and Immunology Early Development, and then latterly taking on responsibility for the Clinical Biomarker team.
Susan joined AZ in September 2010, as Head of the Oncology iMed responsible for Oncology Discovery and early development to Proof of Concept.
CEO of Circassia Limited
Steven Harris is co-founder and CEO of Circassia Limited, a business developing novel products for allergies and auto-immune diseases. Circassia is well funded having raised Ł60m in April 2011 to fund phase III development for its lead programme. Prior to that he was a founder member of the management team that built Zeneus Pharma, following the acquisition of Elan’s European pharmaceutical business.
Over a two-year period the business was restructured, refocused and turned around, and with Mr Harris initially as CFO and subsequently promoted to CEO, Zeneus was acquired in 2006 by US pharmaceutical company Cephalon. Prior to Zeneus, he spent 7 years at PowderJect Pharmaceuticals Plc as CFO, where he helped grow the business from a small loss-making private biotechnology business to a fully integrated and highly profitable publicly-quoted company. PowderJect became the fifth largest vaccines business in the world and was acquired by Chiron for $1 billion in 2003.
Mr Harris is a Chartered Accountant by training having qualified with PriceWaterhouse in 1990.
SVP and Managing Director, MSD and ABPI President Elect
Since taking on the UK appointment in November 2009, Deepak has played an active role in industry-wide affairs, notably as Board Member of the Association of the British Pharmaceutical Industry (ABPI) and Chair of the American Pharmaceutical Group (APG). Deepak will assume the Presidency of the ABPI from April 2012.
In his previous role, Mr Khanna was Senior Vice President and General Manager of Merck/Schering-Plough Pharmaceuticals. He managed all aspects of the U.S. Merck/Schering-Plough Joint Venture and was responsible for the U.S. marketing and sales for the two cardiovascular products jointly marketed by the two companies. After the announcement of plans to merge with Schering-Plough (March 2009), Mr Khanna also led the U.S. integration planning efforts.
Deepak Khanna began his career at Merck in 1988 in field sales and progressed to positions of increasing responsibility within the U.S. Human Health Division. In 1996, Mr Khanna joined the Worldwide Human Health Marketing Division working with rheumatology products; he later assumed responsibility for the marketing planning activities to support early stage central nervous system products. Mr. Khanna rejoined the U.S. Human Health Division in 2001 and assumed leadership responsibilities of the Migraine Franchise Business Group. In January 2003, he was promoted to Vice President of the Atherosclerosis Franchise Business Group.
Mr Khanna holds dual nationality, both British and American. He lives in London with his young family. He earned a Bachelor’s degree in biochemistry and economics from the University of California, Berkeley and an MBA in marketing from Santa Clara University.
Jonathon Mason BSc MSc MPhil DIC MRPharmS ACPP
National Clinical Director for Primary Care and Community Pharmacy, Department of Health, and Clinical Adviser (Medicines), NHS East London and The City
Jonathan is National Clinical Director for Primary Care and Community Pharmacy at the Department of Health, and Clinical Adviser (Medicines) at NHS East London and The City.
Jonathan champions the development of medicines optimisation services which best meet the needs of patients and the public. Jonathan provides clinical leadership to help shape future models of care. He has established a clinical leadership network* to support the development of clinical champions to identify and spread best practice, and to help overcome barriers to service redesign and seamless delivery of care.
Jonathan has a wealth of experience of pharmacy practice, having worked in hospital pharmacy; laboratory-based research into drug metabolism and pharmacokinetics; academia; medicines regulation; and running a busy village pharmacy. Since 1998, Jonathan has worked in primary care pharmacy. *Pharmacists interested in joining the clinical leadership network need to join NHS Networks at http://www.networks.nhs.uk and then apply to join the Pharmacy Clinical Leadership Network. Follow Jonathan on Twitter @jonathanmason
Margaret Mortlock, Pfizer
Margaret Mortlock is a local account manager with Pfizer responsible for working with customers from; NHS Berkshire East, West, Oxford and Buckinghamshire.
She has worked with Pfizer for the past 6 years. Prior to this she was head of primary care for Windsor , Ascot, Maidenhead PCT. She worked in the NHS for 32 years, commencing as a medical secretary, moving into practice management, then implemented the Government’s initiative on clinical audit where she was involved in total quality management project across Thames Valley. Margaret was involved in commissioning services, developing training and education for practice manager and led clinical governance across the PCT. Her passion is partnership working between Pfizer and her NHS customers.
Chief Executive of Ipsos MORI
Ben Page is Chief Executive of Ipsos MORI and sits on the Global Ipsos Management Council. He joined MORI in 1987 after graduating from Oxford University in 1986, and was one of the leaders of its first management buyout in 2000. A frequent writer and speaker on leadership and performance management, he has directed hundreds of surveys examining service delivery, customer care and communications.
Ben has served on a wide range of independent commissions and reviews and is currently a member of the advisory boards of the Kings Fund, Institute of Public Policy Research (IPPR), and the Social Market Foundation (SMF).
Named one of the “100 most influential people in the public sector” by the Guardian, and one of the 50 “most influential” by both Local Government Chronicle and the Health Service Journal, he is a winner of a British Market Research Association (BMRA) award and a 2005 Market Research Society (MRS) medal.
He is absolutely committed to ensuring survey research makes a difference for decision makers.
Dr. Karol Sikora
Karol Sikora is Medical Director of CancerPartnersUK a group creating the largest independent UK cancer network. He was Professor and Chairman of the Department of Cancer Medicine at Imperial College School of Medicine and is still honorary Consultant Oncologist at Hammersmith Hospital, London.
He was Director of the WHO Cancer Programme and still advises the WHO and the UN International Atomic Energy Agency. He was the senior author of IAEA’s recent publication Planning national radiotherapy facilities: a practical tool. He is Dean and Professor of Medicine at Britain’s first independent Medical School at the University of Buckingham and Fellow of Corpus Christi College, Cambridge.
Prof. Richard Sullivan MD PhD
Director, Institute of Cancer Policy & Prof, Cancer Policy & Public Health
As a member of the KHP Integrated Cancer Centre executive he leads on the Centre’s external affairs. Richard is also Visiting Professor (Faculty of Medicine) at Universidad Catolica (Chile), and NATO College as well as a senior fellow at the International Prevention Research Institute, Lyon.
He was formally Director of Clinical Programes at CRUK, and past UK Director of the Council for Emerging National Security Affairs (CENSA) a Washington-based national security think-tank where he specialised security implications of global health. Richard’s research programmes extend from the socio-political policy of global cancer, to the development of public health systems in high-risk conflict areas focusing on DR Congo, Afghanistan & Libya. He also has a strong research interest in the development of novel therapeutics derived from the natural world, particularly medicinal mushrooms.
Richard recently led the first Lancet Oncology Commission that examined the affordability of cancer care in high-income countries.
Managing Director UK, Commercial Solutions for Quintiles
Robert has 20 years’ experience in the industry, including 11 years with Schering Healthcare where his career progressed through senior positions in sales and marketing, both in the UK and Europe. In 2006, he left Schering and joined Quintiles as a Global Project Director. During the next four years Robert successfully led two of Quintiles most innovative, multi-country projects, prior to being appointed Head of UK Commercial Operations in June 2010. In January 2011 he was promoted to Managing Director for UK Commercial Solutions.
Partner in A.T. Kearney’s Global Pharmaceutical Practice
Michael Thomas has over 20 years of consulting experience in pharmaceuticals and healthcare strategy. He has advised a number of companies on pricing and re-imbursement strategies and, more recently, helped companies evaluate alternative value-based re-imbursement models, including novel coverage models for high-cost cancer drugs and partnering models with payers.
He has also supported the pharmaceutical industry in a number of bilateral negotiations with governments across Europe on issues such as P&R, medicines expenditure, patient coverage and entitlements, market access and uptake of new technologies, and industrial policy.
Before joining A.T. Kearney, Michael was EMEA leader for Sales & Marketing in the pharmaceutical practices of IBM and PwC Consulting. He has held a senior management position in Strategy and Planning with SmithklineBeecham, and before entering consultancy ran a PR agency specialising in lifestyle products.
He is a frequent commentator on industry issues and conference speaker.
Prof. Adrian Towse
Director at the Office of Health Economics
He is a Visiting Professor in the Department of Economics and Related Studies at the University of York and has a senior visiting research fellowship at the Department of Public Health at the University of Oxford. He served for 10 years until December 2009 as a Board Member of the Oxford Radcliffe Hospitals NHS Trust, one of the UK’s largest research hospitals, where he chaired the Governance Committee.
Adrian’s current research includes the use of ‘risk-sharing’ arrangements between health care payers and pharmaceutical companies, including value-based pricing approaches; the economics of stratified medicine for health care payers and the pharmaceutical industry; and measuring productivity in health care. His work has included:
• Lecturing and consulting extensively over the last five years on issues relating to pan-European HTA and relative effectiveness issues, most recently at the first Plenary session of ISPOR in Madrid, debating the ‘Pros and Cons of a Centralized European Pricing and Reimbursement Agency,’ with Hans-Georg Eichler of the EMA;
• Working with the Centre for Innovation in Regulatory Science (CIRS) on issues relating to the scientific interaction between regulators and HTA/payer bodies, including the keynote introductory presentation to their April 2010 Workshop on regulator/HTA dialogue;
• Co-chair alongside Lou Garrison of the ISPOR Performance-Based Risk-Sharing Arrangements Good Research Practices Task Force, and a member of the ISPOR Task Force on Prospective Observational Studies;
• Negotiating on behalf of ABPI the 2009 PPRS provisions for Patient Access Schemes in the UK which involve DH and NICE implementing a “fast track” route back to NICE for products not initially found to be cost effective by NICE;
Adrian holds an MA (Hons) in Politics, Philosophy and Economics from Keble College, Oxford; an MPhil in Management Studies from Nuffield College, Oxford, and the Oxford Centre for Management Studies; and is a Member of the Chartered Institute of Management Accountants.
After serving as BBC North America Editor, Justin has joined the team of presenters on Radio 4’s influential Today programme. He now interviews the great and the good and those making the day’s headlines – alongside John Humphrys, Jim Naughtie, Sarah Montague and Evan Davis.
In the US Justin covered all the twists and turns of the Presidential election, making him ideally placed to assess how the post-Bush, recession-fighting administration measures up to the challenge. As well as becoming a senior member of the White House press pack, he remains the only British journalist to be granted a full television interview with President Obama. Justin previously reported from Brussels as the BBC’s European Correspondent. He has also covered elections in Australia, a coup in the Maldives and Mafia trials in Italy. And as well as various overseas postings, he has anchored Breakfast News and The World Tonight.
Chief Executive, ABPI
Stephen Whitehead was appointed to the role of Chief Executive of the Association of the British Pharmaceutical Industry (ABPI) in June 2011. He is the chief advocate for the research-based industry in the UK. Stephen sits on the ABPI Board of Management and is responsible for all aspects of the ABPI’s work. Stephen has in-depth experience of working in regulated industries, has led significant change and modernisation programmes and has extensive experience of developing high performing teams. He has a strong personal passion and commitment to the pharmaceutical industry and earlier in his career spent ten years at GlaxoWellcome and Eli Lilly at UK, European and international level. His expertise is in policy, public affairs, communications, pricing and reimbursement, social policy issues and reputation management. In his last role, Stephen was Group Communications Director at Prudential PLC, one of the world’s largest insurers, a role he held for four years. Prior to this he was Corporate Affairs Director at Barclays PLC after coming from Allied Domecq PLC where he was Group Director of Corporate Affairs. His first of two communications roles in the pharmaceutical industry began with his appointment as Head of Communications at GlaxoWellcome UK where he successfully integrated the global corporate identity of Wellcome following the company’s merger. This was followed by his role at Diageo PLC, where he was Group Alcohol Policy Director and also sat on the board of The Portman Group. Latterly, Stephen was made Director of Corporate Affairs for Eli Lilly’s European operation which involved management of all aspects of external communication from strategy formulation to policy development. Educated at Ilkley Grammar School in West Yorkshire, and then the University of Manchester where he read American Studies, he counts his hobbies as reading political books, dog walking, film and food.